Investors
Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.
Letter from the CEO
Transitioning Towards Late-Stage Development
In 2023, Mendus put in place the building blocks that allow us to transition into a late-stage clinical development company. The positive Phase 2 data with our lead product vididencel in acute myeloid leukemia (AML) presented at the ASH conference in December capped a year with strong progress.
To read the full letter from the CEO, please click here.
Rights Issue and Directed Issue 2023
You will find all relevant information that are published in connection with the proposed rights issue and directed issue in Mendus on this page.
Update on Vididencel Program – Webcast and On-Site Event
Mendus provided an update on its lead program vididencel on Tuesday, June 27, 2023. The update took place in an online event and, separately, on-site at the company’s headquarters in Stockholm, Sweden.
The replay of the online event is accessible via the link below.
Latest press releases
Events
Contact
Telephone
+46 (0)8 732 8400
info@mendus.com
Head Office
Västra Trädgårdsgatan 15
111 53 Stockholm
Sweden
R&D Offices
Emmy Noetherweg 2K
2333 BK Leiden
The Netherlands
Gothenburg Office
Mendus C/O AstraZeneca BioventureHub
Pepparedsleden 1
431 83 Mölndal
Sweden